FDA Orders a Vision-Loss Warning on Every GLP-1 Drug, From Ozempic to Zepbound

The U.S. Food and Drug Administration announced Monday that every GLP-1 medication on the market, including blockbuster weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro and Zepbound, must now carry a warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. The condition cuts off blood flow to the front of the optic nerve and can cause sudden, painless vision loss in one eye. Sometimes that loss is permanent.

The FDA issued the requirement in a Drug Safety Communication on November 9, 2026. Drugmakers must add the new information to the "Warnings and Precautions" section of their product labeling. The agency said NAION cases have been reported with every GLP-1 drug currently sold, which is why the warning covers the whole drug class and not just one medicine.

Key takeaways

• On November 9, 2026, the FDA required makers of all GLP-1 drugs to add a warning about NAION, a rare optic nerve condition linked to sudden vision loss.
• The risk is small: in the FDA's pooled trial data, about 6 cases per 100,000 person-years on a GLP-1 vs. about 4 on comparison treatments.
• Sudden, painless vision loss in one eye, often noticed on waking, needs urgent medical attention.
• Don't stop your medication on your own. Talk with your prescriber first.

What does "label" mean here?

The warning goes into the drug's official prescribing information: the detailed label doctors and pharmacists use, which also appears in the paperwork that comes with your prescription. You probably won't see a new sticker on your pen or box. What changes is the official safety information your care team works from and shares with you.

What the FDA found

The FDA's decision follows two years of growing concern. In July 2024, a study in JAMA Ophthalmology from Massachusetts Eye and Ear linked semaglutide, the active ingredient in Ozempic and Wegovy, to a higher rate of NAION. Among patients with type 2 diabetes, semaglutide users had a 4.28 times higher hazard of NAION than people taking non-GLP-1 diabetes drugs. Among patients with overweight or obesity, the hazard ratio was 7.64. The FDA said the study had limitations but that its findings deserved a closer look.

To get that closer look, the agency pooled data from 126 randomized clinical trials involving more than 134,000 patients.

• 126 — randomized trials pooled in the FDA's analysis
• 134,253 — patients included across those trials
• 6.4 vs 3.8 — NAION cases per 100,000 person-years: GLP-1 users vs. placebo or non-GLP-1 diabetes drugs

That works out to a higher relative rate, but a very small number of actual cases. The FDA also looked at real-world insurance claims data. That analysis found a higher NAION risk with GLP-1 drugs than with DPP-4 inhibitors, another class of diabetes medicine, but no significant increase compared with SGLT-2 inhibitors.

The new U.S. labeling brings the FDA closer to regulators abroad. In 2025, the European Medicines Agency classified NAION as a "very rare" side effect of semaglutide, estimating it may affect up to 1 in 10,000 people taking the drug. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) followed with its own safety update in February 2026.

Keeping risk in perspective

NAION is rare. Even without GLP-1s, it affects an estimated 2 to 10 people per 100,000 each year. Diabetes and obesity, the conditions these drugs treat, are risk factors for NAION too, which makes it hard to separate the drug's effect from the patient's underlying health.

Which drugs are affected?

The requirement applies to every FDA-approved medication with GLP-1 receptor agonist activity, including:

• Ozempic (semaglutide)
• Wegovy (semaglutide)
• Rybelsus (oral semaglutide)
• Mounjaro (tirzepatide)
• Zepbound (tirzepatide)
• Trulicity (dulaglutide)
• Victoza (liraglutide)
• Saxenda (liraglutide)
• Foundayo
• Soliqua
• Xultophy
• Generic exenatide

Eli Lilly, which makes Mounjaro and Zepbound, told CNN that the FDA's communication covers the whole drug class and doesn't point to any findings specific to Lilly products. The company said it is reviewing the update and will respond to the agency promptly.

What is NAION?

NAION is sometimes described as a "stroke in the eye." It happens when blood flow to the front portion of the optic nerve, the cable that carries visual signals from the eye to the brain, suddenly drops. Without enough blood, part of the nerve is damaged. It is the second most common optic nerve condition after glaucoma, and it most often affects people over 50.

There is currently no proven treatment that reverses the damage, which is why early recognition matters.

Know the warning signs

• Sudden vision loss — painless loss of vision in one eye, often noticed upon waking
• Missing areas — blind spots, dark patches or tunnel vision
• Blurry or hazy spots — cloudy areas, especially in the center of vision
• Color changes — colors that look faded or distorted

Who may be at higher risk?

• Adults over 50
• People with diabetes, high blood pressure or high cholesterol
• People with obstructive sleep apnea or low blood pressure at night
• People who smoke or vape
• People with a small, crowded optic disc (sometimes called a "disc at risk"), which an eye doctor can check for
• Anyone who has already had NAION in one eye, since the risk to the other eye is higher

"The risk is rare, but the stakes are high. If your vision suddenly changes, treat it as an emergency."

What patients should do now

• Get help fast. If you notice sudden vision loss or any of the warning signs above, contact your health care provider immediately or go to urgent care or the ER.
• Don't stop your medication on your own. GLP-1 drugs offer proven benefits for diabetes, obesity and heart health, and untreated diabetes and obesity carry their own serious risks, including to your eyes. Talk with your prescriber before making any change.
• If you've had NAION before, ask your doctor whether a GLP-1 drug is still the right choice for you.
• Consider a baseline eye exam. Since 2025, the American Optometric Association has recommended that anyone starting a GLP-1 get an eye exam to check optic nerve health.
• Report side effects to the FDA's MedWatch program at fda.gov/medwatch.

What health care professionals should know

The FDA advises clinicians to promptly refer patients with suspected NAION to an ophthalmologist. If NAION is confirmed, the agency recommends considering stopping the GLP-1 drug unless its benefits clearly outweigh the risks for that patient. Prescribers may also want to ask about eye history and NAION risk factors before starting therapy.

The bigger picture

The FDA's move comes as personal injury lawsuits against Novo Nordisk and Eli Lilly keep growing. Many of those cases claim the companies failed to warn patients about vision risks. Novo Nordisk has called the claims without merit. Legal observers say the new label could shape future cases, since patients starting these drugs now will have the warning in hand.

Scientifically, the question of cause and effect is still open. Some large studies have found no increased risk, and the conditions GLP-1s treat are themselves linked to NAION. Even so, the FDA concluded the signal was strong enough that patients and prescribers should know about it.

For the millions of Americans using GLP-1 medications, the message is about awareness, not alarm. These drugs remain a powerful tool for managing diabetes and weight. Knowing the warning signs of NAION, and acting quickly if they show up, is now part of using them safely.

---

Sources

1. U.S. Food and Drug Administration. Drug Safety Communication: FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare but Serious Eye Condition. November 9, 2026.
2. CNN. "US FDA orders new eye risk warnings for Ozempic, Zepbound." November 9, 2026.
3. The Washington Post. "FDA tells GLP-1 makers to warn of potential vision loss side effect." November 9, 2026.
4. CNBC. "FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound." November 10, 2026.
5. Benzinga. "FDA Flags Potential Vision Loss Risk With GLP-1 Drugs." November 10, 2026.
6. Drugwatch. "FDA Adds Vision Loss Warning to All GLP-1 Drugs." November 9, 2026.
7. UK Medicines and Healthcare products Regulatory Agency. "MHRA updates guidance for semaglutide prescribers and patients." February 5, 2026.
8. MDLinx. Coverage of the 2024 Massachusetts Eye and Ear semaglutide–NAION study (JAMA Ophthalmology).
9. Review of Optometry; ABC News. Coverage of GLP-1s and NAION, 2026.

This article is for informational purposes only and is not medical advice. Always talk with your doctor or pharmacist before starting, stopping or changing any medication.